Clinical trial · no report yet · Phase 3
SYMPATICO
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)
- NCT03112174 ↗
- Completed
- Pharmacyclics LLC.
- 88 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 38 | |
| Podcasts | 25 | |
| X threads | 25 |
The trial
ClinicalTrials.gov- Official title
- Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Mantle-Cell Lymphoma
- Interventions
- Ibrutinib; Venetoclax; Placebo Oral tablet to match Venetoclax
- Arms
- Safety Run-in · Experimental
- Randomization Phase: Ibrutinb + Venetoclax · Experimental
- Randomization Phase: Ibrutinib + Placebo · Placebo comparator
- Treatment-naive Open-label Arm · Experimental
- Enrollment
- 366
- Primary outcomes
- Number of Participants With Tumor Lysis Syndrome (TLS) Events (Safety Run-in)
- Number of Participants With Dose Limiting Toxicities (DLT) (Safety Run-in)
- Number of Participants With Treatment Emergent Adverse Events (TEAEs) (Safety Run-in)
- Progression-free Survival (PFS) (Randomization Phase)
- Complete Response (CR) Rate (Treatment-Naive Arm)
- Sponsor
- Pharmacyclics LLC. with Janssen Research & Development, LLC
- Start
- Jun 19, 2017
- Primary completion
- Jun 26, 2024
- Results posted
- Yes
- Registry record
- NCT03112174 · updated Jul 22, 2025
Publications
linked from the registry- Wang M, Hoffmann MS, Wrobel T, Trneny M, Belada D, Demirken F, Panayiotidis P, Jurczak W, Zinzani PL, Keating MM, Yoon SS, Egyed M, Tam CS, Johnson NA, Szafer Glusman E, Lin J, Dean JP, Neuenburg JK, von Keudell G. First-line ibrutinib plus venetoclax for non-blastoid mantle cell lymphoma in patients >/=65 years or with TP53 mutations. Blood. 2026 Jul 1:blood.2025032833. doi: 10.1182/blood.2025032833. Online ahead of print. PubMed 42462092
- Wang M, Jurczak W, Trneny M, Belada D, Wrobel T, Ghosh N, Keating MM, van Meerten T, Alvarez RF, von Keudell G, Thieblemont C, Peyrade F, Andre M, Hoffmann M, Szafer-Glusman E, Lin J, Dean JP, Neuenburg JK, Tam CS. Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2025 Feb;26(2):200-213. doi: 10.1016/S1470-2045(24)00682-X. PubMed 39914418
- Wang M, Ramchandren R, Chen R, Karlin L, Chong G, Jurczak W, Wu KL, Bishton M, Collins GP, Eliadis P, Peyrade F, Lee Y, Eckert K, Neuenburg JK, Tam CS. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. J Hematol Oncol. 2021 Oct 30;14(1):179. doi: 10.1186/s13045-021-01188-x. PubMed 34717692